Enhancing Therapeutic Efficacy of Double Negative T Cells against Acute Myeloid Leukemia Using Idelalisib.

Kang, Hyeonjeong; Lee, Jong Bok; Khatri, Ismat; Na, Yoosu; D'Souza, Cheryl; Arruda, Andrea; Minden, Mark D; Zhang, Li

Kang, Hyeonjeong; Lee, Jong Bok; Khatri, Ismat; Na, Yoosu; D'Souza, Cheryl; Arruda, Andrea; Minden, Mark D; Zhang, Li.

Afiliación

Kang H; Toronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 2C4, Canada.
Lee JB; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A1, Canada.
Khatri I; Toronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 2C4, Canada.
Na Y; Toronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 2C4, Canada.
D'Souza C; Toronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 2C4, Canada.
Arruda A; Toronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 2C4, Canada.
Minden MD; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada.
Zhang L; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada.

Cancers (Basel) ; 13(20)2021 Oct 09.

Article en En | MEDLINE | ID: mdl-34680188

Palabras clave

PI3K delta inhibitor; acute myeloid leukemia; adoptive T cell therapy; double negative T cell

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2021 Tipo del documento: Article País de afiliación: Canadá

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google